Who makes Incobotulinumoxin A?

Incobotulinumoxin A is developed by Instituto Portugues da Face.

What development phase is Incobotulinumoxin A in?

Incobotulinumoxin A is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Incobotulinumoxin A

Instituto Portugues da Face · FDA-approved active Small molecule Quality 2/100

Incobotulinumoxin A, marketed by Instituto Portugues da Face, holds a position in the neurotoxin market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. However, the primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Incobotulinumoxin A
Sponsor	Instituto Portugues da Face
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Temporomandibular Joint Arthroscopy With Botulinum Toxin Injection Versus Placebo (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Incobotulinumoxin A CI brief — competitive landscape report
Incobotulinumoxin A updates RSS · CI watch RSS
Instituto Portugues da Face portfolio CI